Nu Skin (NYSE: NUS) Q1 2026 sales slip 12% as earnings compress
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Nu Skin Enterprises reported Q1 2026 revenue of $320.6 million, down 12.0% year over year, with a modest +1.1% foreign-exchange benefit. GAAP diluted EPS was $0.04, or $0.14 excluding inventory write-offs, other charges and impairment, compared with $2.14 or $0.23 on an adjusted basis a year ago when results included a large gain from the Mavely sale.
Customers fell 14% to 669,535, Paid Affiliates declined 8% to 120,850, and Sales Leaders decreased 13% to 26,915. Adjusted operating margin was 3.6% versus 6.4% last year. The company returned $2.9 million via dividends and $5.0 million through share repurchases.
For Q2 2026, Nu Skin guides revenue to $330–$360 million with EPS of $0.15–$0.25. Full-year 2026 revenue is projected at $1.35–$1.50 billion and EPS of $0.70–$1.10, or $0.80–$1.20 excluding specified charges, as it invests behind its Prysm iO wellness platform and emerging-market expansion.
Positive
- Maintained 2026 adjusted guidance and liquidity actions – Despite Q1 pressure, Nu Skin kept full-year 2026 adjusted EPS guidance at $0.80–$1.20, refinanced debt to extend liquidity, and still returned $8.0 million to shareholders through dividends and share repurchases.
Negative
- Broad-based volume and earnings decline – Q1 2026 revenue fell 12.0% to $320.6 million, total customers declined 14%, and adjusted EPS dropped to $0.14 from $0.23, with adjusted operating margin compressing to 3.6% from 6.4%.
Insights
Nu Skin shows double-digit top-line pressure and softer margins, but maintains 2026 guidance with new growth initiatives.
Nu Skin delivered Q1 2026 revenue of $320.6 million, down 12.0% year over year, as all major regions declined. Customers fell 14% and Paid Affiliates 8%, signaling a smaller sales and customer base for its core Nu Skin business.
Profitability also compressed. Adjusted operating margin was 3.6% versus 6.4% a year ago, and adjusted EPS was $0.14 compared with $0.23. Prior-year GAAP EPS of $2.14 benefited from a large Mavely sale gain, which does not repeat.
Management still guides 2026 revenue to $1.35–$1.50 billion ((9)% to 1%) and adjusted EPS to $0.80–$1.20, while highlighting the Prysm iO platform and an anticipated India launch in late 2026. The company returned $8.0 million via dividends and buybacks and refinanced debt, supporting liquidity as it navigates the transition.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q1 2026 Revenue: $320.6 million
Q1 2026 GAAP diluted EPS: $0.04
Q1 2026 adjusted EPS: $0.14
+5 more
8 metrics
Q1 2026 Revenue
$320.6 million
Down 12.0% year over year, +1.1% FX impact
Q1 2026 GAAP diluted EPS
$0.04
Versus $2.14 in Q1 2025 with Mavely gain
Q1 2026 adjusted EPS
$0.14
Excluding certain charges; vs $0.23 prior year
Customers
669,535
Three months ended March 31, 2026; down 14%
Q2 2026 revenue outlook
$330–$360 million
Guided decline of 15% to 7% year over year
2026 revenue guidance
$1.35–$1.50 billion
Full-year outlook; (9)% to 1% year-over-year change
2026 EPS guidance
$0.70–$1.10 GAAP; $0.80–$1.20 adjusted
Full-year projected earnings per share range
Shareholder returns Q1 2026
$8.0 million
$2.9M dividends and $5.0M stock repurchases
Key Terms
constant-currency revenue change, non-GAAP financial measures, Prysm iO, Sales Leaders, +1 more
5 terms
constant-currency revenue change financial
"Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates"
non-GAAP financial measures financial
"Earnings per share, gross margin... excluding inventory write-off charges, impairment expense... are non-GAAP financial measures"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
Prysm iO technical
"scale our intelligent wellness platform with our latest innovation, Prysm iO™, ahead of our full consumer rollout"
Sales Leaders financial
"Sales Leaders | | | 26,915; (13)%"
impairment expenses financial
"Impairment expenses | | | $1.8 million impairment compared to $25.1 million impairment"
Impairment expenses are charges a company records when an asset—like a factory, patent or investment—loses value and the company lowers that asset’s reported worth. For investors this matters because impairments reduce reported profits and the company’s balance sheet value, similar to lowering the price on a store item after it’s damaged: it reveals that expected future benefits from that asset are smaller than previously thought, which can change profit trends and risk assessments.
Earnings Snapshot
Revenue: $320.6 million · Guidance included
Q1 2026
Revenue
$320.6 million
-12.0% year over year
GAAP diluted EPS
$0.04
down from $2.14 with prior-year Mavely gain
Adjusted EPS
$0.14
down from $0.23 excluding one-time items
Adjusted operating margin
3.6%
down from 6.4% excluding impairment and other charges
Guidance
For Q2 2026, Nu Skin projects revenue of $330–$360 million and EPS of $0.15–$0.25. Full-year 2026 revenue is guided to $1.35–$1.50 billion with EPS of $0.70–$1.10, or $0.80–$1.20 excluding specified charges.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
||
|
Date of Report (Date of earliest event reported)
|
||
|
|
||
|
(Exact name of registrant as specified in its charter)
|
|
|
|
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
|
|
||
|
(Address of principal executive offices and zip code)
|
||
|
(
|
||
|
(Registrant’s telephone number, including area code)
|
||
|
N/A
|
||
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 |
Results of Operations and Financial Condition.
|
On May 7, 2026, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three-month period ended March 31, 2026, and
certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.
The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits.
|
99.1
|
Nu Skin Enterprises’ press release dated May 7, 2026, regarding financial results for the three-month period ended March 31, 2026.
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
NU SKIN ENTERPRISES, INC.
|
||
|
(Registrant)
|
||
|
/s/ Chelsea K. Lantz
|
||
|
Chelsea K. Lantz
|
||
|
Chief Financial Officer
|
||
|
Date: May 7, 2026
|
||
Exhibit 99.1
FOR IMMEDIATE RELEASE
Nu Skin Enterprises Reports First Quarter Results
PROVO, Utah — May 7, 2026 — Nu Skin Enterprises Inc.
(NYSE: NUS) today announced first quarter revenue results within its guidance range.
Executive Summary
Q1 2026 vs. Prior-year Quarter
|
Revenue
|
$320.6 million; (12.0)%
• +1.1% FX impact or
$3.9 million
|
||
|
Earnings Per Share (EPS)
|
$0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges
|
||
|
Customers
|
669,535; (14)%
|
||
|
Paid Affiliates
|
120,850; (8)%
|
||
|
Sales Leaders
|
26,915; (13)%
|
“We delivered first quarter revenue in line with our expectations and made further progress in our strategic priorities while operating in a volatile environment,” said
Ryan Napierski, Nu Skin president and CEO. “As we move through 2026, we are focused on empowering our sales leaders to scale our intelligent wellness platform with our latest innovation, Prysm iO™, ahead of our full consumer rollout in the second
half. We also continue to invest in laying the groundwork to expand our presence in emerging markets, including the formal launch of India anticipated in late 2026, while continuing to improve our operational discipline to return value to
shareholders.
“We are encouraged by early signs of improving paid affiliates and new sales leader development in several markets as our leaders begin integrating Prysm iO into their
businesses and continue to build upon our leading anti-aging Tru Face® brand. We are focused on partnering with our sales force on leveraging the proprietary nutritional health biomarker tracking from Prysm iO to expand the channel as we prepare to
drive customer subscriptions for our wellness products. While these initiatives will take time to develop, we remain confident that they will increase sales leader engagement and expand our global reach over time to drive the next phase of growth for
Nu Skin.”
|
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
|
page 2
|
Q1 2026 Year-over-year Operating Results
|
Revenue
|
$320.6 million compared to $364.5 million
• +1.1% FX impact or
$3.9 million
|
||
|
Gross Margin
|
66.9% or 67.9% excluding certain charges compared to 67.8%
• Nu Skin business was
76.9% compared to 76.7%
|
||
|
Selling Expenses
|
34.3% compared to 32.5%
• Nu Skin business was
40.5% compared to 38.7%
|
||
|
G&A Expenses
|
30.7% or 29.9% excluding certain charges compared to 31.1% or 28.9% excluding certain charges
|
||
|
Impairment Expenses
|
$1.8 million impairment compared to $25.1 million impairment
|
||
|
Operating Margin
|
1.3% or 3.6% excluding certain charges compared to (2.7)% or 6.4% excluding impairment and other charges
|
||
|
Interest Expense
|
$4.3 million compared to $3.3 million
|
||
|
Other Income (Expense)
|
$2.8 million compared to $(28.4) million
• Prior year reflects
$28.1 million unrealized loss on investment
|
||
|
Income Tax Rate
|
29.4% compared to 20.1%
|
||
|
EPS
|
$0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges
|
Stockholder Value
|
Dividend Payments
|
$2.9 million
|
||
|
Stock Repurchases
|
$5.0 million
• $137.3 million
remaining in authorization
|
Q2 and Full-year 2026 Outlook
|
Q2 2026 Revenue
|
$330 to $360 million; (15)% to (7)%
• Approximately 0% FX
impact
|
||
|
Q2 2026 EPS
|
$0.15 to $0.25
|
||
|
2026 Revenue
|
$1.35 to $1.50 billion; (9)% to 1%
• Approximately (1)% FX
impact
|
||
|
2026 EPS
|
$0.70 to $1.10 or $0.80 to $1.20 excluding certain charges
|
“In addition to delivering on revenue and adjusted earnings, we returned $8 million to
shareholders in the form of dividends and share repurchases,” said Chelsea Lantz, interim chief financial officer. “We were also able to refinance our debt, extending our liquidity as we invest in growth
initiatives and navigate market volatility while executing on our strategy. We are maintaining our annual guidance for 2026 on an adjusted basis. For the second quarter, we project
revenue between $330 million and $360 million, with earnings per share in the range of $0.15 to $0.25.”
|
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
|
page 3
|
Conference Call
The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the
webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company’s website at ir.nuskin.com. A replay of the webcast will be available on the same page through May 21, 2026.
About Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc. (NYSE: NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company’s products
help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal care and wellness products. Rhyz is the strategic investment
arm of Nu Skin Enterprises, formed in 2018 consisting of synergistic consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the
company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s
expectations regarding the company’s performance, growth, initiatives, plans, areas of focus, sales force and customers, shareholder value, Prysm launch and its timing and potential benefits to the business, and emerging market expansion and its
timing; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any
of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “become,” “continue,” “project,” “outlook,” “guidance,” “focus,” “expand,” “will,” “would,” “could,” “may,” “might,” the
negative of these words and other similar words.
|
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
|
page 4
|
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially
from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
| • |
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a
sustained basis;
|
| • |
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner
that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions,
imposition of fines, or any other adverse actions or events;
|
| • |
economic conditions and events globally;
|
| • |
the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets, and
any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets;
|
| • |
competitive pressures in the company’s markets;
|
| • |
risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business;
|
| • |
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;
|
| • |
political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
|
| • |
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business
operations and results;
|
| • |
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;
|
| • |
uncertainties regarding the future financial performance of the businesses the company has acquired;
|
| • |
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of
inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and
|
| • |
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a
market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements.
|
The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated
risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty
to update the forward-looking statements contained in this release to reflect any change except as required by law.
Non-GAAP Financial Measures:
Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by
translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue
change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.
|
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
|
page 5
|
Earnings per share, gross margin, general and administrative expenses, and operating margin, each excluding inventory write-off charges, impairment
expense, the gain from the Mavely sale, unrealized investment loss, and/or other charges, also are non-GAAP financial measures.
| • |
Inventory write-off charges, impairment expense, and unrealized investment loss are not part of the ongoing operations of our underlying business; and
|
| • |
the gain from the Mavely sale, and the other charges incurred in connection with this sale and other corporate actions, are not part of our ongoing operations.
|
The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these items
facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, gross margin, operating margin, income tax rate and revenue growth rate calculated under GAAP, below.
The following table sets forth revenue for the three-month periods ended March 31, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands):
|
Three Months Ended
March 31,
|
Change
|
Constant-
Currency
Change
|
||||||||||||||
|
Nu Skin
|
2026 |
2025 | ||||||||||||||
|
Americas
|
$
|
57,818
|
$
|
69,058
|
(16.3
|
)%
|
(12.6
|
)%
|
||||||||
|
Southeast Asia/Pacific
|
45,474
|
52,172
|
(12.8
|
)%
|
(16.6
|
)%
|
||||||||||
|
Mainland China
|
45,148
|
47,775
|
(5.5
|
)%
|
(10.0
|
)%
|
||||||||||
|
Japan
|
39,739
|
42,765
|
(7.1
|
)%
|
(4.3
|
)%
|
||||||||||
|
Europe & Africa
|
31,218
|
33,021
|
(5.5
|
)%
|
(14.8
|
)%
|
||||||||||
|
Hong Kong/Taiwan
|
27,457
|
28,447
|
(3.5
|
)%
|
(5.9
|
)%
|
||||||||||
|
South Korea
|
25,329
|
32,515
|
(22.1
|
)%
|
(21.4
|
)%
|
||||||||||
|
Nu Skin Other
|
(234
|
)
|
529
|
(144.2
|
)%
|
(144.4
|
)%
|
|||||||||
|
Total Nu Skin
|
271,949
|
306,282
|
(11.2
|
)%
|
(12.5
|
)%
|
||||||||||
|
Rhyz
|
||||||||||||||||
|
Manufacturing
|
44,925
|
55,290
|
(18.7
|
)%
|
(18.7
|
)%
|
||||||||||
|
Rhyz Other
|
3,734
|
2,918
|
28.0
|
%
|
28.0
|
%
|
||||||||||
|
Total Rhyz
|
48,659
|
58,208
|
(16.4
|
)%
|
(16.4
|
)%
|
||||||||||
|
Total
|
$
|
320,608
|
$
|
364,490
|
(12.0
|
)%
|
(13.1
|
)%
|
||||||||
|
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
|
page 6
|
The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods
ended March 31, 2026 and 2025:
|
Three Months Ended
March 31,
|
||||||||||||
|
2026
|
2025
|
Change
|
||||||||||
|
Customers
|
||||||||||||
|
Americas
|
186,448
|
227,514
|
(18
|
)%
|
||||||||
|
Southeast Asia/Pacific
|
67,461
|
74,584
|
(10
|
)%
|
||||||||
|
Mainland China
|
104,721
|
122,474
|
(14
|
)%
|
||||||||
|
Japan
|
102,392
|
107,742
|
(5
|
)%
|
||||||||
|
Europe & Africa
|
115,343
|
130,154
|
(11
|
)%
|
||||||||
|
Hong Kong/Taiwan
|
35,899
|
42,523
|
(16
|
)%
|
||||||||
|
South Korea
|
57,271
|
71,721
|
(20
|
)%
|
||||||||
|
Total Customers
|
669,535
|
776,712
|
(14
|
)%
|
||||||||
|
Paid Affiliates
|
||||||||||||
|
Americas
|
27,039
|
26,936
|
0
|
%
|
||||||||
|
Southeast Asia/Pacific
|
18,163
|
22,296
|
(19
|
)%
|
||||||||
|
Mainland China
|
18,064
|
19,859
|
(9
|
)%
|
||||||||
|
Japan
|
19,224
|
21,073
|
(9
|
)%
|
||||||||
|
Europe & Africa
|
13,607
|
15,184
|
(10
|
)%
|
||||||||
|
Hong Kong/Taiwan
|
9,541
|
9,622
|
(1
|
)%
|
||||||||
|
South Korea
|
15,212
|
16,548
|
(8
|
)%
|
||||||||
|
Total Paid Affiliates
|
120,850
|
131,518
|
(8
|
)%
|
||||||||
|
Sales Leaders
|
||||||||||||
|
Americas
|
4,930
|
6,174
|
(20
|
)%
|
||||||||
|
Southeast Asia/Pacific
|
3,769
|
4,542
|
(17
|
)%
|
||||||||
|
Mainland China
|
5,489
|
6,214
|
(12
|
)%
|
||||||||
|
Japan
|
5,943
|
6,210
|
(4
|
)%
|
||||||||
|
Europe & Africa
|
2,314
|
2,839
|
(19
|
)%
|
||||||||
|
Hong Kong/Taiwan
|
2,123
|
2,207
|
(4
|
)%
|
||||||||
|
South Korea
|
2,347
|
2,850
|
(18
|
)%
|
||||||||
|
Total Sales Leaders
|
26,915
|
31,036
|
(13
|
)%
|
||||||||
| ● |
“Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a
purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.
|
| ● |
“Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides
Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.
|
| ● |
“Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements
as of the end of each month of the quarter.
|
|
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
|
page 7
|
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)
|
Three Months Ended
March 31,
|
||||||||
|
2026
|
2025
|
|||||||
|
Revenue
|
$
|
320,608
|
$
|
364,490
|
||||
|
Cost of sales
|
106,145
|
117,529
|
||||||
|
Gross profit
|
214,463
|
246,961
|
||||||
|
Operating expenses:
|
||||||||
|
Selling expenses
|
110,054
|
118,546
|
||||||
|
General and administrative expenses
|
98,544
|
113,204
|
||||||
|
Impairment expenses
|
1,839
|
25,114
|
||||||
|
Total operating expenses
|
210,437
|
256,864
|
||||||
|
Operating income (loss)
|
4,026
|
(9,903
|
)
|
|||||
|
Interest expense
|
4,250
|
3,283
|
||||||
|
Gain on sale of business
|
-
|
176,162
|
||||||
|
Other income (expense), net
|
2,823
|
(28,375
|
)
|
|||||
|
Income before provision for income taxes
|
2,599
|
134,601
|
||||||
|
Provision for income taxes
|
763
|
27,086
|
||||||
|
Net income
|
$
|
1,836
|
$
|
107,515
|
||||
|
Net income per share:
|
||||||||
|
Basic
|
$
|
0.04
|
$
|
2.16
|
||||
|
Diluted
|
$
|
0.04
|
$
|
2.14
|
||||
|
Weighted-average common shares outstanding (000s):
|
||||||||
|
Basic
|
48,202
|
49,764
|
||||||
|
Diluted
|
49,422
|
50,328
|
||||||
|
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
|
page 8
|
NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)
|
March 31,
|
December 31,
|
|||||||
|
2026
|
2025
|
|||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
198,654
|
$
|
238,630
|
||||
|
Current investments
|
1,751
|
1,211
|
||||||
|
Accounts receivable, net
|
45,013
|
39,544
|
||||||
|
Inventories, net
|
178,600
|
178,643
|
||||||
|
Prepaid expenses and other
|
98,870
|
89,670
|
||||||
|
Total current assets
|
522,888
|
547,698
|
||||||
|
Property and equipment, net
|
381,610
|
377,168
|
||||||
|
Operating lease right-of-use assets
|
70,350
|
74,021
|
||||||
|
Goodwill
|
83,625
|
83,625
|
||||||
|
Other intangible assets, net
|
39,290
|
42,614
|
||||||
|
Other assets
|
279,035
|
280,187
|
||||||
|
Total assets
|
1,376,798
|
1,405,313
|
||||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
28,815
|
$
|
26,183
|
||||
|
Accrued expenses
|
208,182
|
217,551
|
||||||
|
Current portion of long-term debt
|
20,000
|
20,000
|
||||||
|
Total current liabilities
|
256,997
|
263,734
|
||||||
|
Operating lease liabilities
|
54,017
|
57,640
|
||||||
|
Long-term debt
|
203,593
|
204,187
|
||||||
|
Other liabilities
|
68,104
|
74,512
|
||||||
|
Total liabilities
|
582,711
|
600,073
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders’ equity:
|
||||||||
|
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
|
91
|
91
|
||||||
|
Additional paid-in capital
|
613,890
|
635,994
|
||||||
|
Treasury stock, at cost – 42.0 million and 42.4 million shares
|
(1,560,799
|
)
|
(1,575,059
|
)
|
||||
|
Accumulated other comprehensive loss
|
(118,377
|
)
|
(116,105
|
)
|
||||
|
Retained earnings
|
1,859,282
|
1,860,319
|
||||||
|
Total stockholders’ equity
|
794,087
|
805,240
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
1,376,798
|
$
|
1,405,313
|
||||
|
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
|
page 9
|
NU SKIN ENTERPRISES, INC.
Reconciliation of Gross Margin Excluding Impact of Inventory Write-off to GAAP Gross Margin
(in thousands, except for per share amounts)
|
Three months ended
March 31,
|
||||||||
|
2026
|
2025
|
|||||||
|
Gross profit
|
$
|
214,463
|
$
|
246,961
|
||||
|
Impact of inventory write-off
|
3,116
|
-
|
||||||
|
Adjusted gross profit
|
$
|
217,579
|
$
|
246,961
|
||||
|
Gross margin
|
66.9
|
%
|
67.8
|
%
|
||||
|
Gross margin, excluding inventory write-off impact
|
67.9
|
%
|
67.8
|
%
|
||||
|
Revenue
|
$
|
320,608
|
$
|
364,490
|
||||
NU SKIN ENTERPRISES, INC.
Reconciliation of General and Administrative Expenses Excluding Certain Charges to GAAP General and Administrative Expenses
(in thousands, except for per share amounts)
|
Three months ended
March 31,
|
||||||||
|
2026
|
2025
|
|||||||
|
General and administrative expenses
|
$
|
98,544
|
$
|
113,204
|
||||
|
Impact of other charges(1)
|
(2,643
|
)
|
(7,966
|
)
|
||||
|
Adjusted general and administrative expenses
|
$
|
95,901
|
$
|
105,238
|
||||
|
General and administrative expenses as a percentage of revenue
|
30.7
|
%
|
31.1
|
%
|
||||
|
General and administrative expenses as a percentage of revenue, excluding certain charges
|
29.9
|
%
|
28.9
|
%
|
||||
|
Revenue
|
$
|
320,608
|
$
|
364,490
|
||||
(1) Other charges for the first quarter of 2026 consist of $1.0
million related to the wind down of the separate BeautyBio business and $1.6 million of other employee severance charges. Other charges for the first quarter of 2025 consist of expenses incurred in connection with the Mavely sale, including $2.7
million of transaction bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of the Mavely profits interest units.
|
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
|
page 10
|
NU SKIN ENTERPRISES, INC.
Reconciliation of Operating Margin Excluding Certain Charges to GAAP Operating Margin
(in thousands, except for per share amounts)
|
Three months ended
March 31,
|
||||||||
|
2026
|
2025
|
|||||||
|
Operating income (loss)
|
$
|
4,026
|
$
|
(9,903
|
)
|
|||
|
Impact of inventory write-off
|
3,116
|
-
|
||||||
|
Impact of other charges(1)
|
2,643
|
7,966
|
||||||
|
Impact of impairment
|
1,839
|
25,114
|
||||||
|
Adjusted operating income
|
$
|
11,624
|
$
|
23,177
|
||||
|
Operating margin
|
1.3
|
%
|
(2.7
|
)%
|
||||
|
Operating margin, excluding certain charges
|
3.6
|
%
|
6.4
|
%
|
||||
|
Revenue
|
$
|
320,608
|
$
|
364,490
|
||||
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share
(in thousands, except for per share amounts)
|
Three months ended
March 31,
|
||||||||
|
2026
|
2025
|
|||||||
|
Net income
|
$
|
1,836
|
$
|
107,515
|
||||
|
Impact of inventory write-off
|
||||||||
|
Inventory write-off
|
3,116
|
-
|
||||||
|
Tax impact
|
(1,065
|
)
|
-
|
|||||
|
Impact of other charges:
|
||||||||
|
Other charges(1)
|
2,643
|
7,966
|
||||||
|
Tax impact
|
(903
|
)
|
(725
|
)
|
||||
|
Impact of impairment expense:
|
||||||||
|
Impairment
|
1,839
|
25,114
|
||||||
|
Tax impact
|
(629
|
)
|
(5,433
|
)
|
||||
|
Impact of Mavely sale
|
||||||||
|
Gain from Mavely sale
|
-
|
(176,162
|
)
|
|||||
|
Tax impact
|
-
|
31,104
|
||||||
|
Impact of unrealized investment loss
|
||||||||
|
Unrealized investment loss
|
-
|
28,077
|
||||||
|
Tax impact
|
-
|
(6,074
|
)
|
|||||
|
Adjusted net income
|
$
|
6,837
|
$
|
11,382
|
||||
|
Diluted earnings per share
|
$
|
0.04
|
$
|
2.14
|
||||
|
Diluted earnings per share, excluding restructuring impact
|
$
|
0.14
|
$
|
0.23
|
||||
|
Weighted-average common shares outstanding (000)
|
49,422
|
50,328
|
||||||
|
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
|
page 11
|
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share
|
Year ended December 31,
|
||||||||
|
2026 -
Low end
|
2026 -
High end
|
|||||||
|
Earnings Per Share
|
$
|
0.70
|
$
|
1.10
|
||||
|
Impact of inventory write-off
|
||||||||
|
Inventory write-off
|
0.06
|
0.06
|
||||||
|
Tax impact
|
(0.02
|
)
|
(0.02
|
)
|
||||
|
Impact of other charges
|
||||||||
|
Other charges(1)
|
0.05
|
0.05
|
||||||
|
Tax impact
|
(0.02
|
)
|
(0.02
|
)
|
||||
|
Impact impairment expense:
|
||||||||
|
Impairment
|
0.04
|
0.04
|
||||||
|
Tax impact
|
(0.01
|
)
|
(0.01
|
)
|
||||
|
Adjusted EPS
|
$
|
0.80
|
$
|
1.20
|
||||
# # #
CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577
FAQ
How did Nu Skin (NUS) perform financially in Q1 2026?
Nu Skin reported Q1 2026 revenue of $320.6 million, down 12.0% year over year. GAAP diluted EPS was $0.04, or $0.14 excluding inventory write-offs, other charges and impairment, compared with $2.14 or $0.23 on an adjusted basis in the prior-year quarter.
What guidance did Nu Skin (NUS) give for Q2 2026 and full-year 2026?
For Q2 2026, Nu Skin projects revenue of $330–$360 million with EPS of $0.15–$0.25. For full-year 2026, it guides revenue to $1.35–$1.50 billion and EPS of $0.70–$1.10, or $0.80–$1.20 excluding specified charges.
How are Nu Skin’s customers, Paid Affiliates and Sales Leaders trending?
In Q1 2026, total customers declined 14% year over year to 669,535. Paid Affiliates fell 8% to 120,850, while Sales Leaders decreased 13% to 26,915, indicating lower activity across Nu Skin’s core direct-selling network compared with the prior-year period.
What happened to Nu Skin’s profitability and margins in Q1 2026?
Nu Skin’s adjusted operating income was $11.6 million, giving an operating margin of 3.6% excluding specified charges, down from 6.4% a year earlier. Gross margin excluding inventory write-off was 67.9%, roughly flat with 67.8% in the prior-year quarter.
What strategic initiatives is Nu Skin emphasizing for future growth?
Nu Skin is focusing on scaling its Prysm iO intelligent wellness platform, strengthening its Tru Face anti-aging brand, and expanding in emerging markets. Management highlights groundwork for a formal India launch anticipated in late 2026 as part of its longer-term growth strategy.